Genetic Engineering Immune Response Production 
BioTech 365
OCTOBER 28, 2020
RTX-321 Induces Antigen-Specific Stimulation Combined with Broad Stimulation of Innate and Adaptive Immune Responses CAMBRIDGE, Mass., Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an … Continue reading →
pharmaphorum
SEPTEMBER 4, 2020
The treatments are developed using cutting- edge technologies such as genomic sequencing and genetic engineering, helping to account for the individual variability in both patient and disease characteristics. This means not only adopting collaborative thinking during the design phase but also during production and development.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
AUGUST 23, 2021
DNA vaccines work by delivering a genetically-engineered plasmid containing the DNA sequence encoding the desired antigen – in this case the SARS-CoV-2 spike protein – which is then taken up by cells. Proponents of the approach claim that DNA vaccines may have advantages over other technologies like mRNA.
XTalks
NOVEMBER 23, 2020
Oxford-AstraZeneca COVID-19 Vaccine Induces Immune Responses in Early Clinical Trials. As a manufacturing partner for Oxford’s vaccine, AstraZeneca is ramping up its production capabilities as it plans to make up to three billion doses of the vaccine in 2021 on a rolling basis, pending regulatory approval.
Cloudbyz
MARCH 5, 2024
The difference between biologics vs small molecules in pharma drug development In pharmaceutical drug development, biologics and small molecules represent two distinct categories of medicinal products, each with their own unique characteristics, development processes, and mechanisms of action.
The Pharma Data
DECEMBER 16, 2020
Currently in Phase 3 clinical testing in the United Kingdom for the prevention of COVID-19, NVX-CoV2373 is a recombinant protein vaccine adjuvanted with Novavax’ proprietary Matrix-M to enhance the immune response. The company will work with Medsafe, New Zealand’s regulatory agency, to obtain product approvals as needed.
The Pharma Data
NOVEMBER 9, 2020
NVX-CoV2373 was created using Novavax’ recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and contains Novavax’ patented saponin-based Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. Novavax Forward-Looking Statements.
Expert insights. Personalized for you.
40 
Let's personalize your content